{"slug":"btk","tag":"btk","variants":["btk"],"description":"No description yet","count":4,"kinds":{"person":4},"related":[{"slug":"cll","tag":"cll","shared":4},{"slug":"alliance","tag":"alliance","shared":1},{"slug":"australia","tag":"australia","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","tldr":"Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills."},{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","tldr":"Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance."},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","tldr":"Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib."},{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","route":"/people/constantine-tam/","tldr":"Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma."}]}